Enzolytics Inc. (ENZC)
OTHER OTC:ENZC
US Market

Enzolytics (ENZC) Stock Price & Analysis

407 Followers

ENZC Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$0.02 - $0.13
Previous Close$0.05
Volume18.47M
Average Volume (3M)11.55M
Market Cap
$149.78M
Enterprise Value$149.92M
Total Cash (Recent Filing)$7.90K
Total Debt (Recent Filing)$141.15K
Price to Earnings (P/E)-52.2
Beta-0.15
Next EarningsN/A
EPS EstimateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.00
Shares Outstanding2,438,670,097
10 Day Avg. Volume24,476,883
30 Day Avg. Volume11,549,471
Standard Deviation1.50
R-Squared0.00
Alpha0.34
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.25K
Enterprise Value/Gross Profit4.06K
Enterprise Value/Ebitda-23.30
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0


Financials

Annual

ENZC FAQ

What was Enzolytics Inc.’s price range in the past 12 months?
Enzolytics Inc. lowest stock price was $0.02 and its highest was $0.13 in the past 12 months.
    What is Enzolytics Inc.’s market cap?
    Currently, no data Available
    When is Enzolytics Inc.’s upcoming earnings report date?
    The company’s upcoming earnings report date is not yet available.
    How were Enzolytics Inc.’s earnings last quarter?
    Currently, no data Available
    Is Enzolytics Inc. overvalued?
    According to Wall Street analysts Enzolytics Inc.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
      Does Enzolytics Inc. pay dividends?
      Enzolytics Inc. pays a Notavailable dividend of $156.25 which represents an annual dividend yield of N/A. See more information on Enzolytics Inc. dividends here
        What is Enzolytics Inc.’s EPS estimate?
        Enzolytics Inc.’s EPS estimate for its next earnings report is not yet available.
        How many shares outstanding does Enzolytics Inc. have?
        Enzolytics Inc. has 2,880,436,000 shares outstanding.
          What happened to Enzolytics Inc.’s price movement after its last earnings report?
          Currently, no data Available
          Which hedge fund is a major shareholder of Enzolytics Inc.?
          Currently, no hedge funds are holding shares in ENZC

          ---

          Enzolytics Stock Smart Score

          5
          Neutral
          1
          2
          3
          4
          5
          6
          7
          8
          9
          10
          The Enzolytics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
          Learn more about TipRanks Smart Score

          Company Description

          Enzolytics Inc.

          Enzolytics, Inc. is a development stage company, which engages in the research and development on the operations and treatment of HIV/Aids virus. It focuses on the commercialization of the license rights of the IPF for the treatment of Aids and Hepatitis C as well as potential other treatments for life threatening diseases. The company was founded on July 28, 2004 and is headquartered in Monrovia, CA.

          ---

          Forecast EPS vs Actual EPS

          Currently, no data available
          Please return soon. This page is being updated.

          Similar Stocks
          Company
          Price & Change
          Follow
          Larimar Therapeutics
          Icosavax
          Ovid Therapeutics
          X4 Pharmaceuticals
          KalVista Pharmaceuticals

          Popular Stocks

          ---
          What's Included in PREMIUM?
          Make informed decisions based on Top Analysts' activity
          Know what industry insiders are buying
          Get actionable alerts from top Wall Street Analysts
          Find out before anyone else which stock is going to shoot up
          Get powerful stock screeners & detailed portfolio analysis